NSABP B-35

NSABP B-35

• 批准号: 7607606
• 负责人: Scott Henry Kurtzman
• 金额: $ 0.19万
• 依托单位: UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-04-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7607606
• 关键词: Adjuvant; Breast; Computer Retrieval of Information on Scientific Projects Database; Contralateral; Disease-Free Survival; Distant; Double-Blind Method; Effectiveness; End Point; Funding; Grant; Institution; Invasive; Ipsilateral; Life Experience; National Surgical Adjuvant Breast and Bowel Project; Noninfiltrating Intraductal Carcinoma; Patients; Phase; Postmenopause; Quality of life; Radiation; Randomized; Recurrence; Research; Research Personnel; Resources; Second Primary Cancers; Source; Symptoms; Tamoxifen; Time; United States National Institutes of Health; Woman; anastrozole; base; breast lumpectomy; malignant breast neoplasm; osteoporosis with pathological fracture; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This Phase III randomized, double-blind study will evaluate the effectiveness of anastrozole compared to tamoxifen in preventing the subsequent occurrence of breast cancer (local, regional and distant recurrences, and contralateral breast cancer) in postmenopausal women with primary ductal carcinoma in situ (DCIS) treated with lumpectomy and breast radiation. In addition, this study will compare adjuvant anastrozole to tamoxifen in terms of time to invasive breast cancer, ipsilateral recurrence, contralateral breast cancer, other non-breast second primary cancers, osteoporotic fractures, disease-free survival, and overall survival. Also, B-35 will ascertain the effects of anastrozole on patients' symptoms and quality of life as compared to tamoxifen. Analysis will include an endpoint based on survival time adjusted for the quality of life experienced.

这个子项目是众多研究子项目之一